Efficacy and Safety of Activated Recombinant Human Factor VII in Treatment of Bleeding in Patients Following Hematopoietic Stem Cell Transplantation

Stopped Trial enrollment was prematurely terminated due to excessively slow patient recruitment

Conditions

• Acquired Bleeding Disorder
• Bleeding During/Following Surgery

Interventions

• DRUG: standard therapy
• DRUG: placebo
• DRUG: activated recombinant human factor VII
• DRUG: activated recombinant human factor VII

Sponsor

Novo Nordisk A/S